Alkermes plc reported strong top-line growth for the quarter ended June 30, 2026, with total revenues of 496,009 thousand, up from 390,657 thousand a year earlier, but net income declined to 501 thousand from 87,098 thousand as expenses and interest rose.
For the first six months of 2026, revenues grew to 888,920 thousand from 697,167 thousand, while results swung to a net loss of 65,979 thousand, compared with net income of 109,562 thousand in 2025, largely reflecting the February 2026 acquisition of Avadel Pharmaceuticals.
The Avadel transaction carried preliminary consideration of 2,306,920 thousand, added 1,794,900 thousand of identifiable intangibles and 511,246 thousand of goodwill, and was financed with new term loans totaling 1,525,000 thousand, driving interest expense of 46,817 thousand and negative operating cash flow of 20,560 thousand year to date.
Alkermes plc reported Q2 2026 total revenues of $496.0 million, compared with $390.7 million a year earlier, driven by proprietary net sales of $411.7 million, including VIVITROL $124.5 million, ARISTADA $96.7 million, LYBALVI $94.0 million and newly acquired LUMRYZ $96.6 million.
GAAP net income for the quarter was $0.5 million versus $87.1 million in Q2 2025, reflecting higher R&D and SG&A, $22.6 million of amortization of acquired intangibles and a $26.4 million increase in contingent consideration tied to the Avadel acquisition. Adjusted EBITDA was $139.2 million, compared with $126.5 million.
At June 30, 2026, cash, cash equivalents and investments were $691.6 million, alongside a larger asset base following the Avadel transaction. Full‑year 2026 revenue and product‑level net sales guidance were reaffirmed, but GAAP net loss expectations were widened to $95–$115 million and EBITDA guidance reduced to $75–$95 million, while Adjusted EBITDA guidance remained $370–$410 million. Blair Jackson is scheduled to become CEO on August 1, 2026, with current CEO Richard Pops continuing as chairman.
Alkermes plc terminated its Authorized Generic Product Supply Agreement with Amneal Pharmaceuticals LLC on July 6, 2026. The agreement had allowed Amneal to distribute a limited quantity of an authorized generic version of VIVITROL in the United States for a one-year term tied to a third-party ANDA product launch.
The arrangement provided Alkermes Pharma Ireland Limited with payment at a premium to fully burdened manufacturing cost plus a share of any net profits from sales. After Alkermes notified Amneal that certain terms were not met and allowed time to remedy, Amneal informed Alkermes that it did not wish to order any batches.
Alkermes did not incur any penalties from ending the agreement, and no further payments or obligations are owed by either party. Both sides also agreed to release all claims against each other and their affiliates related to the agreement.
Alkermes plc. executive David Joseph Gaffin, EVP and Chief Legal Officer of Alkermes, Inc., reported an open-market sale of 2,034 Ordinary Shares on July 6, 2026 at $54.03 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. Following this sale, he directly holds 227,490 Ordinary Shares, so the transaction represents only a small fraction of his overall position.
Alkermes plc files a notice of proposed sale of Common Stock under Rule 144 by a selling holder. The excerpt lists proposed sales by David Gaffin of 70,315.38, 67,528.80 and 87,563.70 on 04/06/2026, 05/04/2026 and 06/04/2026, respectively.
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported a combination of option exercise and share sales in Ordinary Shares. He exercised employee stock options for 5,000 shares at a conversion price of $19.34 per share and, on the same date, sold a total of 9,000 Ordinary Shares in open-market transactions at weighted average prices of $51.4613 and $52.1314. The filing notes these transactions were executed under a Rule 10b5-1 trading plan adopted on March 14, 2025. Following the transactions, he directly holds 73,389 Ordinary Shares and 1,356 employee stock options.
Alkermes plc reported proposed dispositions of Ordinary Shares via Form 144 associated with insider transactions. The excerpt lists four monthly sales of 9,000 shares each on 03/02/2026, 04/01/2026, 05/01/2026, and 06/01/2026 with gross proceeds of $267,485.14, $319,604.00, $300,559.55, and $375,043.23, respectively. The filing also records a broker-assisted cashless exercise of 5,000 shares on 07/01/2026 and vesting of 4,000 shares as a performance award on 02/05/2026.
Alkermes plc reported that alixorexton, its investigational orexin 2 receptor agonist for sleep disorders, has received orphan drug designations in both the U.S. and Europe. The FDA granted orphan status for idiopathic hypersomnia, while the European Commission granted orphan status for narcolepsy.
Alixorexton is in phase 3 Brilliance studies for narcolepsy types 1 and 2 and in the phase 2 Vibrance-3 study for idiopathic hypersomnia. Orphan designation can provide tax credits, reduced regulatory fees and market exclusivity, supporting development of this potential treatment for rare, chronic neurological conditions.
Alkermes plc director Christopher I. Wright reported an open-market sale of 2,000 Ordinary Shares at a price of $45.10 per share. After this transaction, he directly holds 25,680 Ordinary Shares.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted by Wright on March 11, 2026, indicating the trade was scheduled in advance rather than timed discretionarily.
Alkermes plc submitted a Rule 144 notice related to 2,000 shares of Common Stock tied to the vesting of restricted stock unit awards on 05/21/2026. The filing lists a shares outstanding figure of 166,675,807 as of 06/12/2026 as context.